CJC-1295 with DAC
Long-acting GHRH analog with Drug Affinity Complex
Overview
CJC-1295 with DAC is the long-acting member of the Modified GRF 1-29 family. The structural difference is a maleimido-propionyl group at Lys30 that reacts covalently with Cys34 of human serum albumin in vivo, the Drug Affinity Complex (DAC) mechanism that gives the SKU its name. The resulting peptide-albumin conjugate circulates with kinetics close to albumin itself, stretching plasma half-life from roughly 30 minutes (no-DAC) to about 6-8 days and supporting once-weekly dosing in both compounding and research contexts. Vialdyne releases CJC-1295 with DAC as the lyophilised acetate against a ≥99.0% main-peak HPLC specification. The DAC variant carries a more demanding analytical burden than the no-DAC form: the maleimido group has to remain intact at the labelled position to retain in vivo albumin-binding activity, and a partially hydrolysed maleimide passes the standard HPLC purity gate at near-identical retention time but is pharmacokinetically inactive. The standard release packet covers peak-integration RP-HPLC plus ESI-MS at the modified mass; an intact-maleimide reactivity assay using a reference thiol target (typically cysteine or N-acetyl-cysteine) is offered as a documented add-on and is the recommended qualification test both at first-time pharmacy onboarding and on any batch where stability comes into question. The DAC PK profile fits sustained-elevation GH preparations and weekly-dosing compounding workflows; for pulse-pharmacology contexts the no-DAC CJC-1295 SKU is the appropriate alternative.
Who buys this, and why
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
- CAS
- 863288-34-0
- Appearance
- White lyophilized powder
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 2 mg, 5 mg
- MOQ
- On request
- Lead time
- 10–18 days
- Storage
- -20°C, protect from light
Documentation available on request
- Certificate of Analysis (COA)
- HPLC Chromatogram
- Mass-spec identity (ESI-MS)
- Counter-ion (acetate vs TFA)
- Sterile-fill release pack (sterility, CCI, fill-weight)
- Bacterial endotoxin (LAL, USP <85>)
- Stability data on request
- SDS / MSDS
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Frequently asked questions
What does the 'DAC' modification actually do at a molecular level?▾
DAC stands for Drug Affinity Complex. The chemistry is a maleimido-propionyl group attached at Lys30 of the Modified GRF 1-29 backbone. Once in circulation, the maleimide reacts covalently with the free thiol of Cys34 on human serum albumin, producing a long-circulating peptide-albumin conjugate. Human serum albumin has a plasma half-life of roughly 19 days, so the conjugated peptide inherits similar circulation kinetics, dramatically extended from the ~30-minute half-life of the unmodified no-DAC form. The same in vivo bioconjugation strategy underwrites several approved peptide drugs in other therapeutic areas.
How should I choose between CJC-1295 with DAC and without DAC?▾
PK profile, not potency, is the selection axis. The no-DAC form delivers a ~30-minute half-life and a pulsatile GH-release pattern that preserves natural pulse architecture, typical dosing is every several hours. The DAC form delivers a ~6-8 day half-life and sustained GH elevation, which overrides the natural pulse pattern but supports once-weekly dosing. Research workflows that need pulse pharmacology or natural GH-release-pattern modelling require the no-DAC form, the DAC version eliminates the pulse signal entirely. Sustained-elevation research and any 503A compounding context where weekly dosing is the operational goal point to the DAC form.
Why is intact-maleimide confirmation an important analytical concern for the DAC form?▾
Because the DAC mechanism depends entirely on the maleimide remaining covalent-reactive. A hydrolysed maleimide, which can form during improper storage or handling, opens to the carboxylic acid and loses albumin-conjugation activity, but it sits at near-identical RP-HPLC retention time and a very similar mass, so the standard release HPLC and ESI-MS will not catch the difference. The diagnostic test is a reactivity assay against a reference thiol such as cysteine or N-acetyl-cysteine, which directly confirms the maleimide is still functional. This is the qualification test we recommend at first-time supplier onboarding and on any batch where the receiving pharmacy has stability questions.
Related peptides
Buyers who view CJC-1295 with DAC also ask about:
CJC-1295 (no DAC)
≥99.0%Modified GRF 1-29 · GHRH analog
- CAS
- 863288-34-0
- Vial
- 2 mg–10 mg
Ipamorelin
≥99.0%Ghrelin / GHSR pathway GH-release peptide
- CAS
- 170851-70-4
- Vial
- 2 mg–10 mg
29-mer
Sermorelin
≥99.0%GHRH 1-29 fragment
- CAS
- 86168-78-7
- Vial
- 2 mg–10 mg